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646Objective: A robust release of endothelin-1 with subsequent endothelin-A subtype receptor activation occurs in
patients after cardiac surgery requiring cardiopulmonary bypass. Increased endothelin-A subtype receptor activa-
tion has been identified in patients with poor left ventricular function (reduced ejection fraction). Accordingly,
this study tested the hypothesis that a selective endothelin-A subtype receptor antagonist administered perioper-
atively would favorably affect post-cardiopulmonary bypass hemodynamic profiles in patients with a preexisting
poor left ventricular ejection fraction.
Methods: Patients (n ¼ 29; 66  2 years) with a reduced left ventricular ejection fraction (37%  2%) were
prospectively randomized in a blinded fashion, at the time of elective coronary revascularization or valve replace-
ment requiring cardiopulmonary bypass, to infusion of the highly selective and potent endothelin-A subtype
receptor antagonist sitaxsentan at 1 or 2 mg/kg (intravenous bolus; n ¼ 9, 10 respectively) or vehicle (saline;
n¼ 10). Infusion of the endothelin-A subtype receptor antagonist/vehicle was performed immediately before separa-
tion from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass. Endothelin and hemody-
namic measurements were performed at baseline, at separation from cardiopulmonary bypass (time 0), and at 0.5,
6, 12, and 24 hours after cardiopulmonary bypass.
Results: Baseline plasma endothelin (4.0  0.3 fmol/mL) was identical across all 3 groups, but when compared
with preoperative values, baseline values obtained from age-matched subjects with a normal left ventricular ejec-
tion fraction (n ¼ 37; left ventricular ejection fraction>50%) were significantly increased (2.9  0.2 fmol/mL,
P<.05). Baseline systemic (1358 83 dynes/sec/cm5) and pulmonary (180 23 dynes/sec/cm5) vascular resis-
tance were equivalent in all 3 groups. As a function of time 0, systemic vascular resistance changed in an equiv-
alent fashion in the post-cardiopulmonary bypass period, but a significant endothelin-A subtype receptor
antagonist effect was observed for pulmonary vascular resistance (analysis of variance; P< .05). For example,
at 24 hours post-cardiopulmonary bypass, pulmonary vascular resistance increased by 40 dynes/sec/cm5 in
the vehicle group but directionally decreased by more than 40 dynes/sec/cm5 in the 2 mg/kg endothelin-A sub-
type receptor antagonist group (P<.05). Total adverse events were equivalently distributed across the endothelin-
A subtype receptor antagonist/placebo groups.
Conclusion: These unique findings demonstrated that infusion of an endothelin-A subtype receptor antagonist in
high-risk patients undergoing cardiac surgery was not associated with significant hemodynamic compromise.
Moreover, the endothelin-A subtype receptor antagonist favorably affected pulmonary vascular resistance in
the early postoperative period. Thus, the endothelin-A subtype receptor serves as a potential pharmacologic target
for improving outcomes after cardiac surgery in patients with compromised left ventricular function. (J Thorac
Cardiovasc Surg 2010;139:646-54)Cardiopulmonary bypass (CBP) remains a mainstay for the
performance of cardiac surgical procedures, including coro-
nary artery bypass grafting (CABG) and valve replacement.
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Abbreviations and Acronyms
AE ¼ adverse event
ANOVA ¼ analysis of variance
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
ET ¼ endothelin
ET-ARA ¼ endothelin-A receptor antagonist
LV ¼ left ventricular
RV ¼ right ventricular
SAE ¼ serious adverse event
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Dpost-CPB period and can affect important determinants of
postoperative recovery, such as systemic, pulmonary, and
coronary conduit vascular tone.1-8 More complex CABG
procedures (eg, repeat revascularization and concomitant
valve repair/replacement) and preexisting comorbidities
(eg, increased age and left ventricular [LV] systolic dysfunc-
tion) in patients have been associated with increased risk for
a complex postoperative course.9-15 However, the mechanis-
tic relationship between ET receptor signaling and early
postoperative hemodynamics, particularly in patients with
preexisting LV dysfunction, has not been examined. Ac-
cordingly, the overall goal of this study was to examine
the early postoperative indices of systemic and pulmonary
vascular resistance after administration of an ET receptor
in older patients who have preexisting LV dysfunction and
are undergoing CABG, valve replacement, or combined pro-
cedures requiring CPB.
ET mediates several biologic and physiologic responses
through 2 primary receptor subtypes: the ET-A and B recep-
tors.4-8 In past studies, nonselective ET receptor antagonists
(those that inhibit ET binding to both the ET-A and B recep-
tors) have been used in several cardiovascular disease states,
including systemic arterial hypertension, and in patients with
compromised LV function.1,2,16-19 However, outcomes from
the use of these nonselective ET receptor antagonists, partic-
ularly in patients with reduced LV systolic dysfunction,
were equivocal or actually worsened clinical status.16-19
These past results were likely due, at least in part, to the
distinctly different receptor transduction pathways inherent
to the ET-A and B receptors. Specifically, ET-A receptor
activation causes increased activation of certain protein
kinase-C isoforms, which in turn mobilizes calcium and
ultimately vascular smooth muscle vasoconstriction.4,6 In
addition, ET-A receptor activation has been shown to exac-
erbate myocyte contractile dysfunction after simulated car-
dioplegic arrest.20 In contradistinction, ET-B receptor
activation is coupled to nitric oxide synthesis pathways,
which will in turn promote vascular smooth muscle relaxa-
tion, particularly in the pulmonary vasculature.5,7 Moreover,
the ET-B receptor binds circulating ET within theThe Journal of Thoracic and Capulmonary circuit and thereby forms an important clearance
pathway for this bioactive peptide.21 Taken together, this
would suggest that selective ET-A receptor inhibition in
which the ET-B receptor remains unopposed would be of
potential hemodynamic benefit. Accordingly, highly selec-
tive ET-A receptor antagonists (ET-ARAs) have been devel-
oped. One prototypical, highly selective (6500:1, ET-A vs
ET-B) and potent (Ki ¼ 0.43 nM) ET-ARA is sitaxsentan,
which has been used in oral formulation in patients with pul-
monary arterial hypertension.22,23 In a recently completed
dose-ranging study by this laboratory, an intravenous formu-
lation of this ET-ARA was safely administered to patients
after CABG and CPB.24,25 However, this past study was per-
formed in patients with minimal comorbidities and normal
LV function. Accordingly, the present study was performed
with 2 specific aims: (1) evaluate the effects of intravenous
administration of a selective ET-ARA in older patients
with preexisting LV systolic dysfunction in the post-CPB
period with respect to overall safety and hemodynamic sta-
bility, and (2) examine whether and to what degree ET-ARA
administration affected systemic and pulmonary vascular re-
sistance properties in the post-CPB period, in this particular
group of patients.
MATERIALS AND METHODS
Patients
After approval by the Human Subjects Review Committee of the Med-
ical University of South Carolina (HR16252), patients undergoing
CABG, aortic or mitral valve replacement, or combined CABG and valve
procedures requiring CPB were initially evaluated for study eligibility.
The inclusion criteria were age more than 60 years and an LV ejection frac-
tion of less than 50% documented by a preoperative echocardiogram; dia-
betic patients were to have a fasting glucose less than 350 mg/dL or recent
hemoglobin A1c level less than 9%, or if hypertensive, be on a stable med-
ical regimen with no significant changes during the past 30 days. Although
the study was conducted at several institutions, a larger proportion of pa-
tients were recruited from the Ralph H. Johnson Veterans Affairs Medical
Center, which resulted in a larger number of male patients eligible for enroll-
ment. The exclusion criteria included emergency revascularization, stroke
or thromboembolic event within 3 months before surgery, recent (<7
days) myocardial infarction, documented coagulopathy, or hepatic dysfunc-
tion as defined by aspartate transaminase or alanine transaminase more than
1.5 times the upper limit of normal. If the patient met these criteria, informed
consent was obtained.
Operative Procedure
Standard induction and maintenance of anesthesia were accomplished
with a combination of sufentanil, midazolam, and isoflurane. Appropriate
monitoring lines (radial artery and pulmonary artery catheters) were
placed. Before CPB, systemic heparinization was accomplished with a hep-
arin dose of 400 U/kg. Additional heparin was administered during CPB to
maintain an activated clotting time of more than 400 seconds. CPB was
maintained at a cardiac index of 2.0 to 2.4 L/min/m2 with a Stockert-Shiley
roller pump (Shiley Inc, Irvine, Calif) using a Sarns membrane oxygenator
(Terumo/Sarns, Ann Arbor, Mich). The pump prime consisted of 1200 mL
of normothermic, lactated Ringer’s solution, to which 500 mL of hetas-
tarch, 25 meq of sodium bicarbonate, and 1000 units of heparin were
added; however, retrograde autologous priming was performed whenever
possible before initiation of CPB. Initial cardioplegic arrest wasrdiovascular Surgery c Volume 139, Number 3 647
TABLE 1. Preoperative demographics and perioperative variables for
patients randomized to vehicle or endothelin-A receptor antagonist
sitaxsentan
ET-ARA
Vehicle 1mg/kg 2mg/kg P value
Preoperative
Age (y) 67  2 62  3 68  3 .242
LVEF (%) 35  3 38  2 37  3 .762
Hypertensive (n) 9/10 6/9 8/10 .273
Diabetic (n) 7/10 4/9 6/10 .483
Gender (M/F) 9/1 7/2 10/0 .283
CABG only (n) 7/10 8/9 7/10 .546
Valve replacement (n) 1/10 0/9 0/10 .374
CABG valve (n) 2/10 1/9 3/10 .596
Diuretics (n) 3/10 1/9 7/10 .025
Reoperation(n) 0/10 1/9 4/10 .051
Plasma ET (fmol/mL) 3.9  0.4 3.7  0.3 4.3  0.7 .786
Intraoperative
Crossclamp time (min) 74  12 88  10 75  4 .488
CPB time (min) 103  16 101  9 107  10 .921
Postoperative
Intubation time (h) 23  3 24  8 32  13 .689
ICU time (d) 6  1 5  1 10  3 .183
Length of stay (d) 10  1 11  3 17  4 .239
LVEF, Left ventricular ejection fraction; CABG, coronary artery bypass grafting;
ET, endothelin; ET-ARA, endothelin-A receptor antagonist; CPB, cardiopulmonary
bypass; ICU, intensive care unit. Vehicle n ¼ 10, 1 mg/kg n ¼ 9, 2 mg/kg n ¼ 10.
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mL of a solution of D5/0.2 NaCL containing 29 mL of tromethamine
buffer, 34 mL of adenosine citrate phosphate dextrose, and 60 meq of
KCL (120 meq/L) in a 4:1 blood:crystalloid mixture. This was followed
immediately with retrograde administration of 1000 mL of hypothermic
cardioplegic solution. Every 20 minutes cardioplegic arrest was maintained
with 250 to 500 mL retrograde administration of the cardioplegic solution
with a reduced potassium concentration (60 meq/L), and a 500 mL termi-
nal normothermic cardioplegic shot was given before crossclamp removal.
Patients were not actively cooled while on CPB and were rewarmed to
a rectal temperature of 36.5C before separation. At the termination of
CPB, heparin was neutralized with protamine in a 1:1 ratio. Nitroglycerin
infusion was administered postoperatively for systemic hypertension (de-
fined as a 20% increase over preoperative levels) and ST segment eleva-
tion or depression of greater than 1 mm. Epinephrine infusion was
administered postoperatively to maintain a cardiac index of greater than
2.0 L/min/m2 when needed. Discharge criteria from the intensive care
unit included complete weaning from all vasoactive and inotropic infu-
sions, extubation without pulmonary support, and no evidence of major or-
gan failure. Discharge criteria from the hospital included stable sinus
rhythm, no supplemental oxygen requirement, ambulation, normal bowel
and bladder function, and tolerance of oral intake.
Endothelin-1-A Receptor Antagonist
The ET-ARA used in this study was sitaxsentan sodium (TBC11251Na),
which has been described.22-26 This study was performed under Food and
Drug Administration Investigational New Drug 52,527. It has been demon-
strated that this ET-ARA quickly reaches a steady-state level (within 30
minutes) after intravenous administration and has a half-life of approxi-
mately 6 hours.22,26 Sitaxsentan has been safely used in patients with pri-
mary pulmonary hypertension.22,23 More recently, we demonstrated that
intravenous sitaxsentan can be safely administered to patients undergoing
elective CABG and CPB with no preexisting risk factors.24,25 Moreover,
these past studies demonstrated that both 1 and 2mg/kg infusion doses influ-
enced both pulmonary hemodynamics and bioactive signaling. On the basis
of these past results, the present study used a 1 and 2 mg/kg ET-ARA infu-
sion protocol that was formulated in sterile saline within 2 hours of systemic
infusion. The vehicle for this study was an equal volume of sterile saline.
Study Protocol
After informed consent, 29 patients were randomized to the following 3
treatment groups using a predetermined randomization coding scheme that
was developed before the initiation of the study and maintained in a blinded
fashion by the study coordinator (J.M.): (1) vehicle (saline vehicle bolus); (2)
1 mg/kg of ET-ARA; and (3) 2 mg/kg of ET-A antagonist. The vehicle or
ET-ARA was infused immediately at separation from CPB as a bolus infu-
sion over 5 minutes and then again at 12 hours post-CPB. The initial time
point of infusion, which corresponded to when the infusion was complete
and the patient was removed from CPB, was designated as time 0. With
this as the reference, the following time points were used: baseline (after
placement of arterial and pulmonary catheters, but before the onset of
CPB), time 0 (immediately at cessation of CPB and after placebo/drug infu-
sion), 0.5 hours post-CPB, 6 hours post-CPB, 12 hours post-CPB, and 24
hours post-CPB. The hemodynamic measurements obtained and computed
at each of these time points were heart rate, mean arterial pressure, mean pul-
monary artery pressure, cardiac output, systemic vascular resistance, and pul-
monary vascular resistance. At the designated time points, blood samples
were collected to determine plasma ET using radioimmunoassay methods
well described by this laboratory.3,24,25 In addition, plasma concentrations
of the ET-ARA sitaxsentan were determined by a precalibrated high-perfor-
mance liquid chromatography method described previously.26 In the postop-
erative period, inotropic and vasodilator requirements were recorded. All
adverse events (AEs) were adjudicated, reviewed, and reported to the Med-
ical University of South Carolina Institutional Review Board.648 The Journal of Thoracic and Cardiovascular SurgData Analysis
Hemodynamic parameters and plasma ET-1 levels at each time point
were evaluated with a multiway analysis of variance (ANOVA). If the AN-
OVA revealed significant differences, pairwise tests of individual group
means were compared by adjusted probabilities (Bonferroni method). Cat-
egoric variables, such as demographics and preoperative variables, were ex-
amined by chi-square analysis. Changes in pulmonary and systemic
vascular resistance were computed as follows. First, the absolute values at
baseline and the designated time points were examined by ANOVA. Sec-
ond, the change in the main response variables, such as systemic and pulmo-
nary vascular resistance, was examined as a function from time 0 because
this was the index time point for this study with respect to treatment and sep-
aration from CPB. Next, pairwise comparisons in the changes in these pa-
rameters were performed using adjusted probabilities. All statistical
procedures were performed using STATA statistical software (STATA In-
tercooled V 8.0.; StataCorp LP, College Station, Tex). Results are presented
as mean  standard error of the mean.RESULTS
Demographic, intraoperative, and postoperative descrip-
tive data for the 29 patients enrolled in this study are pre-
sented in Table 1. The main preoperative risk variables of
interest, age, and LV ejection fraction were equivalent
across the patients randomized to the vehicle and 1 and 2
mg/kg ET-ARA groups. All other preoperative data were
similar across groups with the exception of the number of
patients presenting for a reoperation (all a secondary revas-
cularization procedure,>1 year from previous procedure)
and diuretic use, in which a higher number of these patients
were randomized to the 2 mg/kg group. Baseline plasma ETery c March 2010
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FIGURE 1. Preoperative (baseline) plasma ET-1 values were determined
in patients with a normal LVEF (n ¼ 37, defined as> 50%) undergoing
elective cardiac surgery from a study recently performed using identical
high-sensitivity immunoassay procedures24 and compared with baseline
plasma ET values obtained from the present study in patients with a reduced
LVEF (n ¼ 29,<50%). The distribution of individual values from these 2
patient groups is shown, where the mean baseline ET level was 2.9  0.2
fmol/mL in the normal LVEF group and was significantly increased in pa-
tients with reduced LVEF (4.0  0.2 fmol/mL, *P< .05). LVEF, Left ven-
tricular ejection fraction.
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Dlevels were equivalent across all 3 treatment groups. How-
ever, when the composite baseline plasma ET levels were
compared with previously obtained preoperative ET levels
in patients undergoing elective CABG with a normal LV
ejection fraction,24 the baseline ET levels obtained in the
present study were significantly higher (Figure 1). Aortic
crossclamp time and total CPB times were similar between
groups, as were overall time to extubation, intensive care
unit stay, and total length of hospital stay (Table 1).Hemodynamics and Endothelin Levels After
Cardiopulmonary Bypass
Absolute values for heart rate, mean arterial blood pres-
sure, pulmonary artery pressure, and systemic and pulmo-
nary vascular resistance, and plasma ET and ET-ARA
values at baseline and the designated post-CPB time points
are shown in Table 2. Baseline hemodynamics were equiv-
alent in patients randomized to the vehicle or 1 or 2 mg/kg
ET-ARA groups. Pairwise comparison results are shown
in Table 2, and the ANOVA results are summarized for he-
modynamic variables in this paragraph. Heart rate increased
as a function of post-CPB time (F¼ 10.2, P¼ .001) and was
higher in the ET-ARA groups at later post-CPB time points.
Mean arterial pressure decreased at early post-CPB time
points, and this was a significant time effect (F ¼ 6.68, P
¼ .001). Pulmonary artery pressures tended to increase in
the post-CPB periods, and a significant treatment effect onThe Journal of Thoracic and Cathis hemodynamic value was observed (F ¼ 5.17, P ¼
.007). Cardiac output was increased in the early postopera-
tive time points in the ET-ARA groups. Systemic vascular
resistance decreased in the post-CPB time periods with
both time (F ¼ 5.03, P ¼ .001) and treatment (F ¼ 4.10, P
¼ .018) effects, and this parameter decreased to the greatest
degree in the 2 mg/kg ET-ARA group. Pulmonary vascular
resistance changed in a time-dependent manner post-CPB
(F ¼ 2.20, P ¼ .058). Plasma ET levels increased in the
post-CPB period (F ¼ 15.45, P ¼ .001), and higher values
were observed in the 2 mg/kg group. Plasma levels for the
ET-ARA sitaxsentan immediately after infusion, at the 6-
hour time point, immediately after the second infusion at
12 hours, and at the 24-hour time point are shown in Table
2. At 6 hours after the first infusion of the ET-ARA, a signif-
icant reduction in plasma drug concentrations was observed.
At 24 hours after the second ET-ARA infusion, drug levels
were at minimal detectable levels, consistent with the clear-
ance kinetics of this compound.26 Because a high degree of
within-patient variation in systemic and pulmonary vascular
resistance occurred at baseline and post-CPB time points,
these indices were transformed as a function of time 0 to
more carefully examine potential treatment effects. There
were no significant differences in the relative change in sys-
temic vascular resistance with respect to treatment (AN-
OVA, F ¼ 0.13, P ¼ .88). However, the relative change in
pulmonary vascular resistance was significantly affected
by treatment, with the greatest reduction in this parameter
in the 2 mg/kg group at the late post-CPB time points
(Figure 2).
Adverse Events
A total of 168 AEs were tabulated in the postoperative pe-
riod, and a categoric distribution of these AEs is presented in
Table 3. The total number of AEs was not significantly dif-
ferent among the 3 groups (P ¼ .09). AEs were equally dis-
tributed across treatment groups with 1 exception: the
hematologic/lymphatic category, for which a higher percent-
age was reported in the 2 mg/kg group. The preponderance
of these AEs in the 2 mg/kg group (10) was secondary to low
postoperative hematocrit that occurred in 5 patients as the re-
sult of increased perioperative blood loss. These AEs were
adjudicated not to be study related. There were 18 serious
adverse events (SAEs) reported. These SAEs included 3 pa-
tient deaths that occurred in the 1 mg/kg ET-ARA (n ¼ 2)
and the 2 mg/kg ET-ARA (n¼ 1) groups and that were con-
sidered unrelated to ET-ARA treatment after adjudication.
One patient with a significantly low (<30%) preoperative
ejection fraction died of low cardiac output and respiratory
failure on the second postoperative day. On review, this
poor postoperative course may have been precipitated by
a protamine reaction, thereby exacerbating the preexisting
LV dysfunction. The second patient died of sudden cardiac
arrest during a routine incentive spirometry session onrdiovascular Surgery c Volume 139, Number 3 649
TABLE 2. Hemodynamics at baseline and after cardiopulmonary bypass in patients randomized to vehicle or endothelin-A receptor antagonist
sitaxsentan
Post-CPB (h)
Baseline 0 6 12 24
Heart rate (beats/min)
Vehicle 62.6  3.7 77.8  2.9 75.2  3.8 78.5  5.6 78.6  4.1
1 mg/kg ET-ARA 63.6  2.0 80.1  4.6 85.1  6.4* 88.2  3.2* 91.7  6.6*
2 mg/kg ET-ARA 62.4  2.8 84.5  5.2* 85.6  5.2* 84.5  5.5* 85.9  4.2*
Arterial pressure (mm Hg)
Vehicle 82.8  3.9 72.5  3.7 76.1  3.5 72.9  2.8 80.5  4.3
1 mg/kg ET-ARA 80.7  4.8 69.0  4.6 75.3  3.0 70.2  3.0 80.9  2.3
2 mg/kg ET-ARA 80.1  3.2 71.9  4.0 73.9  2.8 72.6  1.6 80.1  2.3
Pulmonary artery
pressure (mm Hg)
Vehicle 20.4  1.4 20.8  2.2 23.8  2.3 24.6  1.4 22.9  1.5
1 mg/kg ET-ARA 25.7  3.6 19.3  2.4 22.4  1.4 22.1  2.0 24.2  2.3
2 mg/kg ET-ARA 25.3  4.2 26.0  3.3 28.4  3.2 26.4  1.8 26.6  2.4
Cardiac output (L/min)
Vehicle 4.4  0.3 4.8  0.4 5.2  0.4 5.4  0.4 5.3  0.5
1 mg/kg ET-ARA 4.4  0.6 5.5  0.7 5.9  0.8* 6.8  0.7* 6.9  0.8*
2 mg/kg ET-ARA 4.3  0.2 5.5  0.4 6.1  0.4* 5.5  0.2 5.6  0.4
Systemic vascular
resistance (dynes/sec/cm5)
Vehicle 1408  119 1155  165 1106  157 962  98 1192  158
1 mg/kg ET-ARA 1359  210 894  159 1068  193 761  71 898  115
2 mg/kg ET-ARA 1307  112 960  89* 820.7  67* 897  46* 1015  86
Pulmonary vascular resistance
(dynes/sec/cm5)
Vehicle 153.8  19.9 123.5  20.7 138.7  28.0 146.8  21.6 163.3  26.6
1 mg/kg ET-ARA 213.0  65.3 125.3  24.8 144.6  15.2 132.7  12.7 125.5  22.3
2 mg/kg ET-ARA 174.6  28.4 175.8  26.6 132.7  17.6 136.6  17.5 138.7  20.0
Plasma ET-1 (fmol/mL)
Vehicle 3.9  0.4 5.5  0.8 8.2  1.1* 8.6  1.1* 8.0  1.0*
1 mg/kg ET-ARA 3.7  0.3 4.7  0.5 7.2  1.3 8.8  1.7* 8.3  1.0*
2 mg/kg ET-ARA 4.3  0.7 4.1  0.5 7.6  1.2 10.4  1.6* 8.6  1.4*
Sitaxsentan levels (mg/mL)
1 mg/kg ET-ARA N/A 7.35  0.83 0.06  0.01 1.88  1.26 0.06  0.01
2 mg/kg ET-ARA N/A 11.78  1.17y 2.24  2.13 8.63  3.24y 0.09  0.01
CPB, Cardiopulmonary bypass; ET-ARA, endothelin-A receptor antagonist. Vehicle, n¼ 10; 1 mg/kg, n¼ 9; 2 mg/kg, n¼ 10. *P<.05 vs baseline. yP<.05 vs 1 mg/kg ET-ARA.
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discharge). The third patient died of presumed cardiopulmo-
nary failure 38 days postoperatively in an outlying facility.
The other SAEs were cardiovascular (thromboembolic
event, bleeding, n ¼ 8), pulmonary/infection (n ¼ 6), and
gastrointestinal (ischemic bowel, n ¼ 1). When the SAEs
were considered as a composite, there were no significant
differences among treatment groups (chi-square 1.59; P ¼
.452).
DISCUSSION
Increased synthesis and release of the peptide ET-1 occur
in several cardiovascular disease states and bind to 2 pre-
dominant receptor subtypes: the ET-A and B receptors.
The most studied effects are that of ET binding to the ET-
A receptor, which causes significant vasoconstriction, influ-650 The Journal of Thoracic and Cardiovascular Surgences excitation-contraction coupling processes, and mod-
ifies sympathetic efferent firing and chronotropy within the
myocardium.1–8,20,27–31 In marked contrast, ET binding to
the ET-B receptor mediates the release of nitric oxide and
causes relaxation of vascular smooth muscle.1,2,7,16-18,21,32,33
In light of these differential effects, selective ET-ARAs
have been developed and deployed in cardiovascular disease
states such as pulmonary hypertension.16,18,22 Past studies
have demonstrated that increased ET release occurs in
patients after cardiac surgery requiring CPB and may con-
tribute to a complex postoperative course.3,24,25,34 In an ini-
tial dose-ranging pilot study in patients undergoing elective
CABG requiring CPB, the ET-ARA antagonist sitaxsentan
was well tolerated and caused a dose-dependent decrease
in pulmonary vascular resistance in the post-CPB period.25
This initial study was performed in low-risk patients withery c March 2010
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FIGURE 2. Changes in pulmonary vascular resistance, computed in abso-
lute units, from time 0 (vehicle/ET-ARA infusion and separation from
CPB). In the early post-CPB period, an ET-ARA effect was observed for
pulmonary vascular resistance (ANOVA, F¼ 4.73, P¼ .01). Pairwise com-
parisons showed a significantly lower pulmonary vascular resistance
24hours post-CPB (*P< .05 vs vehicle).
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However, patients with preexisting risk factors, such as
LV systolic dysfunction and complex medical histories (ie,
hypertension, diabetes, increased age), who present for car-
diac surgery are those with a higher incidence of postopera-
tive morbidity and mortality.9-15 Thus, if inhibition of the
ET-A receptor is to be considered a viable therapeutic target
in cardiac surgery, then an ET-ARA must be evaluated in
higher-risk patients undergoing cardiac surgery. Accord-
ingly, by using a blinded and randomized protocol, the pres-
ent study infused vehicle or 1 or 2 mg/kg of the ET-ARA
sitaxsentan in patients with preexisting LV dysfunction at
the time of separation from CPB and at 12 hours post-
CPB. This initial study demonstrated that the ET-ARA could
be used in high-risk patients and that the higher dose of sitax-
sentan attenuated the degree of pulmonary vasoconstriction
in the post-CPB period. This study adds to the growing body
of evidence that inhibition of the ET-A receptor may be
a viable therapeutic target in the context of cardiac surgery
requiring CPB.
Synthesis and release of the bioactive molecule ET occur
within all cell types and organ systems, particularly within
the cardiovascular system.16-20 Although the role of ET in
systemic hypertension and heart failure has been the focus
of both basic and clinical studies,17-19,28,33 the primary ther-
apeutic target has been that of primary pulmonary hyperten-
sion. Specifically, oral formulations of both nonselective and
ET-A subtype selective antagonists have been described to
be efficacious in pulmonary hypertension.16,18,22 However,
an oral formulation of an ET-ARA would not be of practical
clinical use in an acute care setting, and therefore infusible
formulations of selective ET-ARAs would be required.
This laboratory has described basic and clinical studies usingThe Journal of Thoracic and Caan intravenous formulation of the ET-ARA sitaxsen-
tan.24,25,35 These past studies demonstrated a significant re-
duction in pulmonary vascular resistance post-CPB.25,35
However, these studies were performed in the context of
normal LV function, whereas a preponderance of patients
may present for cardiac surgery with preexisting LV myo-
cardial dysfunction and other comorbidities, such as diabe-
tes. Previous work demonstrated that the density and
distribution of myocardial ET-A receptor subtypes may be
increased in LV dysfunction, and that the sensitivity of ET
can be enhanced with diabetes.33,36,37 The present study
was the first to demonstrate that an infusible ET-ARA
used in patients with significant preexisting cardiac surgical
risk factors influenced pulmonary vascular resistance in the
early postoperative period. However, this study used only 1
highly selective ET-ARA, and therefore it remains to be es-
tablished whether this is a class effect that can be achieved
with other selective ET-ARAs.
In the present study, conventional hemodynamic monitor-
ing was performed at prespecified intervals before and after
vehicle or ET-ARA administration. In both the 1 and 2 mg/
kg ET-ARA groups, heart rate increased in the post-CPB pe-
riod. This increased chronotropy with ET-ARA treatment
does not seem to have been caused by a baroreceptor reflex
response, because arterial blood pressure remained un-
changed at these post-CPB time points. Rather, it has been
reported that ET has a direct negative effect on chronotropy
and that ET receptor inhibition has a positive chronotropic
effect, likely because of local sympathetic effects on sino-
atrial nodal cells.29-31 There are 2 important considerations
regarding the potential positive chronotropic effect of the
ET-ARA that was observed in the present study. First, the
increased heart rate can significantly affect cardiac output
and in turn influence the resistance calculations. Cardiac out-
put was increased to the greatest degree in the ET-ARA
groups in the postoperative period. Second, heart rate is an
important determinant of myocardial oxygen demand, and
therefore the chronotropic effect of ET-ARA infusion may
not be a desirable effect in the early postoperative period.
A past study by this laboratory demonstrated that exogenous
ET caused potent vasoconstriction of vascular conduits used
in CABG, and that selective ET-ARAs inhibited this effect.3
Thus, although not directly measured in the present study,
infusion of an ET-ARA in the early post-CPB period may
have several effects on myocardial oxygen demand and
blood flow.
In general terms, baseline hemodynamics were similar
across the randomized groups, but there was some intrinsic
variability in these measurements likely because of varying
degrees of cardiopulmonary compromise in patients. Be-
cause the true intervention used in this study did not occur
until vehicle/ET-ARA infusion and separation from CPB,
time 0 was the point that was used as the index event. Ac-
cordingly, the relative changes in key hemodynamicrdiovascular Surgery c Volume 139, Number 3 651
TABLE 3. Adverse events in high-risk patients after cardiopulmonary bypass randomized to vehicle or endothelin-A receptor antagonist
sitaxsentan
Sitaxsentan
Adverse event Vehicle 1mg/kg 2mg/kg Total Chi-square P value
Cardiovascular 12 20 17 49 2 .368
% 24% 41% 35% 100%
Pulmonary 3 4 8 15 2.8 .246
% 20% 27% 53% 100%
Neurologic 2 0 0 2 0.5 .779
% 100% 0% 0% 100%
Urinary 2 0 3 5 1.0 .606
% 40% 0% 60% 100%
Gastrointestinal 9 8 8 25 0.1 .961
% 36% 32% 32% 100%
Hepatic 0 3 1 4 1.6 .449
% 0% 75% 25% 100%
Musculoskeletal 1 7 5 13 4.3 .116
% 8% 54% 38% 100%
Genitourinary/gynecologic 0 0 0 0 n/a n/a
% 0% 0% 0% 0%
Endocrine/metabolic 1 1 5 7 4.6 .102
% 14% 14% 71% 100%
Immunologic/allergic 0 1 0 1 2.3 .316
% 0% 100% 0% 100%
Hematologic/lymphatic 1 4 10 15 8.4 .015
% 7% 27% 67% 100%
Psychologic/behavioral 3 4 7 14 1.9 .395
% 21% 29% 50% 100%
HEENT 1 0 0 1 2.0 .374
% 100% 0% 0% 100%
Infection 3 0 2 5 1.0 .606
% 60% 0% 40% 100%
Fever 0 3 4 7 1.8 .417
% 0% 43% 57% 100%
Dermatologic 0 3 2 5 1.0 .606
% 0% 60% 40% 100%
HEENT, Head, eyes, ears, nose, and throat.
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this analysis, the most significant treatment effect was that
observed with respect to pulmonary vascular resistance in
the later post-CPB time points. One potential contributory
factor for the relative changes in pulmonary vascular resis-
tance observed in the ET-ARA groups was an increase in
cardiac output. However, the greatest increase in cardiac
output was observed in the 1 mg/kg ET-ARA group,
whereas the greatest reduction in pulmonary vascular resis-
tance was observed in the 2 mg/kg ET-ARA group, which is
consistent with the pharmacologic effects of ET-ARAs in
general and our past reports using this infusible ET-
ARA.25 In addition, the greatest reduction in systemic vas-
cular resistance was observed in the 2 mg/kg ET-ARA
group. However, more sensitive and direct effects on vascu-
lar compliance and the potential effects of ET-ARAwere not
evaluated in the present study. It has been clearly demon-652 The Journal of Thoracic and Cardiovascular Surgstrated that ET receptor inhibition causes a direct vasodila-
tory effect within the pulmonary vasculature.16-18 Taken
together, the mechanisms that underlie the effects of
ET-ARA on pulmonary vascular resistance were likely com-
binatorial and included increased cardiac output and direct
effects on pulmonary vascular tone.
The current study predicated the 2 doses of the ET-ARA
on the results of past dose ranges in patients undergoing
elective CABG with normal LV ejection fraction.25 The ra-
tionale for the timing of the ET-ARA infusions was based on
previous observations regarding the temporal dynamics of
ET release in the post-CPB period and the pharmacokinetics
of ET-ARA itself.24-26,34 Specifically, the release of ET post-
CPB seems to occur in a biphasic manner in which an initial
surge occurs immediately after separation from CPB and
a second peak occurs at approximately 12 hours after
CPB.24,34 Thus, the present study was designed to targetery c March 2010
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the ET-ARA immediately post-CPB and 12 hours post-
CPB. Consistent with the pharmacokinetics of sitaxsentan,
plasma levels of this ET-ARA were detectable at 6 hours af-
ter bolus infusion of the 2 mg/kg dose, but were nominal by
12 hours after bolus infusion.26 In light of this, the direct
pharmacologic effects of the ET-ARA that were observed
in the present study would not likely persist beyond 12 hours
after dosing. Thus, because steady-state hemodynamics and
pulmonary vascular resistance did not abruptly increase at
the 24-hour post-CPB time point, a significant autoregula-
tory or pharmacologic ‘‘rebound effect’’ may not be opera-
tive with this dosing regimen. However, several issues
warrant consideration for the pharmacologic use of this
ET-ARA in cardiac surgery. First, longer monitoring periods
will be necessary to fully examine the hemodynamic effects
of the ET-ARA infusion protocol used in the present study.
Second, a larger prospective study is necessary to determine
whether the effects of this infusible ET-ARA cause dose-de-
pendent effects on pulmonary vascular resistance and
whether 2 mg/kg of the ET-ARA is a maximally effective
dose in a high-risk cardiac surgical population.
The present study examined plasma ET levels in patients
with preexisting LV dysfunction preoperatively and after
CPB. The first important observation from these measure-
ments was that preoperative, steady-state plasma ET levels
were higher in patients with preexisting LV systolic dys-
function when compared with preoperative ET levels mea-
sured under identical conditions in an age-matched cohort
of patients with normal LV systolic function.24,25 Increased
plasma ET levels have been reported in patients with signif-
icant heart failure.17-19,33 Thus, the increased plasma ET
levels are likely reflective of the pathophysiologic conse-
quences of LV dysfunction. Although remaining specula-
tive, the present study provides evidence to suggest that
preoperativemeasurements of plasma ETmay serve as a bio-
marker for patients at increased risk for ET-mediated events,
such as increased pulmonary vascular resistance, in the post-
CPB period. A larger prospective study will be necessary to
directly address this issue. Consistent with past re-
ports,24,25,34,35 plasma ET levels increased significantly in
the post-CPB period, which is likely the result of increased
synthesis and spillover from interstitial compartments,
such as the myocardium.33,34 In the ET-ARA groups,
plasma ET levels were increased to the greatest degree in
the post-CPB period. The reasons for the increased circulat-
ing levels of ET with infusion of the ET-ARA are likely 2-
fold. (1) Inhibition of the ET-A receptor likely interrupts a re-
ceptor-transduction feedback pathway and thereby may in-
duce increased synthesis and release of ET. (2) Occupancy
of the ET-A receptor with the antagonist will displace bound
ET and therefore cause a reflective increase in plasma levels.
The highest levels of ET occurred 12 hours after CPB, when
a second infusion of the ET-ARA was delivered, whichThe Journal of Thoracic and Cawould lend support for the displacement of bound ET to
cognate ET-A receptors. Although the increased plasma
levels of ET in the late post-CPB period in the ET-ARA
groups is likely a summation of these factors, the increased
plasma ET is evidence for a pharmacologic effect of the
ET-ARA.
Because sitaxsentan is a potent and selective ET-ARA,
the increased levels of ET may cause heightened binding
and activation of the ET-B receptor. The increased activation
of the ET-B receptor in turn may cause increased nitric oxide
release and vascular smooth muscle relaxation, particularly
in the pulmonary vasculature. Thus, a potential indirect path-
way by which ET-ARA infusion facilitated a reduction in
pulmonary vascular resistance in the post-CPB period was
through increased and unopposed activation of the pulmo-
nary ET-B receptor. The selective reduction in pulmonary
vascular resistance may hold particular relevance in patients
with preexisting right ventricular (RV) failure or in whom
RV failure develops perioperatively. Specifically, a relative
reduction in RV afterload may be beneficial in the early post-
operative period, particularly because RV failure is not an
uncommon occurrence in the context of cardiac surgery.36,37
However, this issue was not directly addressed in the present
study.
The present study was the first to use a selective ET-ARA
in patients undergoing cardiac surgery with significant pre-
operative risk factors. Because of the advanced age and
poor LV systolic performance of these patients, it was not
surprising there were a number of AEs encountered during
the course of the study. One of the first major limitations
of this study was the small sample size, which in turn can re-
sult in a disproportionate number of patients with greater
preoperative risk profiles randomized to 1 treatment group.
Indeed, a significantly greater number of patients random-
ized to the 2 mg/kg ET-ARA group presented for reopera-
tion and had increased diuretic dependency. All 5
reoperations were randomized to an ET-ARA group, 4 of
these to the 2 mg/kg group. The increased incidence of
low hematocrit/hemoglobin in the early postoperative period
in the 2 mg/kg ET-ARA group may have been due in part to
the increased perioperative bleeding that can occur in reop-
eration. Speculatively, diuretic dependence may be an indi-
cator of more advanced heart failure. Notably, despite
a higher preoperative risk profile in the 2 mg/kg ET-ARA
group, the total number of AEs and SAEs was not signifi-
cantly increased. The 3 patients who died in this study had
a significant preoperative risk, and their deaths were adjudi-
cated not to be associated with ET-ARA treatment. Further-
more, the statistical analysis suggests the deaths that
occurred in the ET-ARA groups were strictly due to chance.
Nevertheless, these outcomes coupled with the limited sam-
ple size of this initial feasibility study warrant a note of cau-
tion that can only be further addressed by a larger
prospective study.rdiovascular Surgery c Volume 139, Number 3 653
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DCONCLUSIONS
In patients with preexisting LV systolic dysfunction, in-
creased ET-A receptor activation likely contributes to
changes in hemodynamic profiles after cardiac surgery re-
quiring CPB, and therefore constitutes a viable therapeutic
target.
The authors thank Theresa A. Brinsa for assistance with data
analysis.
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